A study has identified a potential way to address anti-PD-1 treatment resistance in hepatocellular carcinoma (HCC), a common form of liver cancer. The research focuses on the fibroinflammatory liver microenvironment, or FILM, which is prevalent in HCC and linked to reduced responses to immune checkpoint therapy.
According to the findings, FILM limits GSDME-dependent pyroptosis, an inflammatory form of programmed cell death. This suppression is associated with an immune-suppressive environment that can weaken the effectiveness of anti-PD-1 treatment.
The authors report that activating PPARα can counter these effects by promoting GSDME-dependent pyroptosis in HCC. The proposed mechanism connects PPARα activity with changes in the tumor microenvironment and the restoration of an immune response.
The findings position PPARα as a possible therapeutic target for overcoming microenvironment-associated anti-PD-1 resistance in liver cancer, while highlighting the role of pyroptosis in the interaction between tumor cells and immune regulation.
